LCP Health Analytics is partnering with COTA to explore how US real-world data (RWD) can support health technology assessments (HTA) in the United Kingdom (UK) and European Union (EU). With growing recognition that European patients may be underserved by delays in accessing new health technologies, this initiative explores whether deidentified US multiple myeloma patient data can be leveraged to inform reimbursement decisions and accelerate access to new treatments in the UK.
By combining COTA’s rich oncology data with LCP’s analytical expertise supporting HTA decision-making, this partnership will develop and test methods for identifying US patient groups that closely resemble those treated under NHS guidelines in the UK. This collaboration represents the first direct comparison of US and UK real-world haematological oncology data, offering unique insights and addressing historical challenges in cross-country data access and use in the UK.
Once comparable groups are identified, the project will undertake several steps to evaluate their suitability for inclusion in UK and EU HTAs. Evaluative criteria include:
- Characterisation of patient groups using clinical and demographic data
- Examination of treatment patterns and key outcomes, such as survival rates, relevant to payers and HTA bodies
- Assessment of the potential to use these groups in future real-world studies to emulate clinical trial populations.
This partnership, leveraging COTA’s US oncology real world dataset, directly follows LCP Health Analytics’ recent expansion through launching their US Access Solutions in earlier this year.
COTA’s high-quality, comprehensive oncology real-world data (RWD) is sourced from electronic health records and reflects a 50/50 mix of academic and community care settings across the US. Its suite of artificial intelligence abstraction and curation tools will help remove the barriers to faster, more efficient RWD analyses and insight generation at scale. Historically, the UK has relied on US clinical trial data for regulatory approvals and HTA evaluations while seeking country-specific RWD. This collaboration aims to bridge that gap. By incorporating diverse US RWD from COTA, we hope to achieve a more comprehensive understanding of the methods for identifying UK relevant treatment groups and how these cohorts can be used to support groundbreaking developments reaching the right patients, at the right time.
